AstraZeneca AB

• A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination with Chemotherapy for the First Line Treatment for Pati… Not authorised
  2022-502043-35-00 Phase III 4 countries CARBOPLATIN; CISPLATIN; DURVALUMAB; GEMCITABINE; INFLIXIMAB; MYCOPHENOLATE MOFET…
• A trial to learn how ceralasertib affects the way certain medications move throughout the body over time and how safe it is to use ceralaser… Not authorised
  2024-516611-24-00 Phase I (Other) 1 country
• A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases (CLIPS) Pending
  2023-508533-14-00 Phase III 3 countries BENRALIZUMAB
• A trial to learn how well Dato-DXd and rilvegostomig work and how safe they are in participants with stage I adenocarcinoma non-small cell l… Pending
  2024-512195-35-00 Phase III 9 countries DATOPOTAMAB DERUXTECAN; RILVEGOSTOMIG
• A study to evaluate the efficacy, immunogenicity, and safety of an RSV and hMPV VLP vaccine compared with placebo in participants aged 60 ye… Pending
  2024-513740-28-00 Phase III 8 countries IVX-121, HUMAN METAPNEUMOVIRUS, VIRUS-LIKE PROTEIN
• A trial to learn how safe AZD9793 is, how it moves throughout the body over time, how it affects the body, and how well it works in adults w… Pending
  2024-516698-56-00 Phase I (FiH) 1 country AZD9793
• A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants with Advanced or Metastatic Non-Small Cel… Pending
  2024-519786-22-01 Phase I/II 7 countries RAMUCIRUMAB; RILVEGOSTOMIG
• A trial to learn how well sonesitatug vedotin and capecitabine with or without rilvegostomig work and how safe they are in adults with cance… Pending
  2024-519787-40-00 Phase III 8 countries AZD0901; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; INFLIXIMAB; MYCOPHENOLATE MOF…
• A study to learn how safe AZD6621 is, how well it works, and how it moves throughout the body over time, in adult male participants with Met… Pending
  2025-520626-37-00 Phase I (FiH) 5 countries AZD6621
• A study to investigate how well and safe a trial drug called AZD1163, administered as an injection, works in improving symptoms and inflamma… Pending
  2025-522076-85-00 Phase II 5 countries AZD1163
• A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma. Pending
  2025-523285-25-00 Phase III 6 countries AZD0120; BORTEZOMIB; CARFILZOMIB; DARATUMUMAB; DEXAMETHASONE; POMALIDOMIDE
• A trial to learn how safe newer immunotherapy drugs are and how well they work with or without other anti-cancer drugs in adults with advanc… Pending
  2025-523599-21-00 Phase II 2 countries RILVEGOSTOMIG
• A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythema… Pending
  2025-523670-17-00 Phase III 5 countries ANIFROLUMAB
• A Phase II study to investigate lung function with 2 different doses of inhaled glycopyrronium taken with BFF compared to BFF in participant… Pending
  2025-524914-26-00 Phase II 3 countries FORMOTEROL FUMARATE, BUDESONIDE; GLYCOPYRRONIUM BROMIDE
• A trial to learn how safe different combinations of anti-cancer drugs are and how well they work in adults with advanced or metastatic non-s… Recruiting
  2025-524843-11-00 Phase II 3 countries RILVEGOSTOMIG
• A trial to learn how safe AZD9750 is and how well it works in people with metastatic prostate cancer when given with or without other antica… Recruiting
  2024-516976-14-00 Phase I (FiH) 2 countries AZD9750; SARUPARIB
• Study of Volrustomig as Monotherapy or in Combination with Anti- cancer Agents in Participants with Advanced/Metastatic Solid Tumors Recruiting
  2025-523947-36-00 Phase II 2 countries VOLRUSTOMIG
• MAVRiC studies 2L treatment with AV in patients with CLL/SLL who have relapsed after a course of BTKi + BCL2i combination, with and without … Recruiting
  2024-518858-17-00 Phase II 6 countries ACALABRUTINIB; VENETOCLAX
• A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab. Recruiting
  2025-521639-34-00 Phase I (Other) 1 country DURVALUMAB; DURVALUMAB, HYALURONIDASE (HUMAN RECOMBINANT); TREMELIMUMAB
• A study to investigate safety, tolerability, pharmacokinetics, and pharmacodynamics of surovatamig in adult participants with rheumatoid art… Recruiting
  2025-522273-10-00 Phase I (Other) 3 countries
• A Global Phase III Study of Puxitatug Samrotecan (AZD8205) Monotherapy Compared with Physician’s Choice of Chemotherapy for B7-H4-Selected E… Recruiting
  2024-518777-34-00 Phase III 15 countries AZD8205
• A trial to learn how safe AZD3632 is, how well it works, and how it moves throughout the body over time in adults with acute leukemia and my… Recruiting
  2025-521299-76-00 Phase I (FiH) 3 countries AZD3632
• Phase 3 Study of T-DXd and Rilvegostomig versus Standard of Care in Advanced HER2-expressing Biliary Tract Cancer Recruiting
  2023-508057-19-00 Phase III 10 countries DURVALUMAB; RILVEGOSTOMIG; TRASTUZUMAB DERUXTECAN
• A study to test the safety and efficacy of a new drug, AZD3470, in patients with advanced solid tumours. Recruiting
  2023-506757-38-00 Phase I 3 countries AZD3470; DEXTROMETHORPHAN HYDROBROMIDE; MIDAZOLAM

Showing 1–24 of 280 trials